In vivo effect of novel antibody prototype in Immuno-oncology
| Reference number | |
| Coordinator | Genagon Therapeutics - GENAGON THERAPEUTICS AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | June 2017 - November 2018 |
| Status | Completed |
Important results from the project
The purpose of the project was to investigate the effect in vivo of antibodies developed by Genagon, raised against a previously not studied signaling pathway for tumor treatment. In collaboration with the group of Ass.Prof Sara Mangsbo, Uppsala University the antibodies previously validated by the company were tested. Strong data was obtained, where one the "lead candidate" therapeutic mAb demonstrated superior qualities in vivo. The company can then further progress the antibody towards "candidate drug" phase, for a preclinical and clinical stage.
Expected long term effects
Several of the mAbs had strong effect in vivo, with previously not observed effects in tumor treatment, with a novel mechanism of action (MoA). The antibody with superior qualities rendered displayed macroscopic complete responses. In whole group in average approx. 70 % reduction in tumor burden.
Approach and implementation
The study was designed initially to investigate effect of antibodies in tumor models in vivo. The tests generated very good effect data, and a priority was given to understand the MoA to find indications for the clinical path ahead. Extensive analysis of the proteomic profile was combined with analysis of subtypes of immune cells in the tumor micro environment. The data demonstrated a link between secreted key proteins-biomarkers- and subtypes of immune cells targeted. The conclusion is that the antibody has a unique therapeutic niche not known to be addressed by other products.